<DOC>
	<DOCNO>NCT01719380</DOCNO>
	<brief_summary>This study ass safety efficacy LGX818 combine cetuximab combine cetuximab BYL719 patient BRAF mutant metastatic colorectal cancer</brief_summary>
	<brief_title>Study LGX818 Cetuximab LGX818 , BYL719 , Cetuximab BRAF Mutant Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Metastatic colorectal cancer Progression least one prior standard care regimen intolerant irinotecanbased regimen Life expectancy ≥ 3 month ECOG performance status ≤ 2 Symptomatic untreated leptomeningeal disease Symptomatic brain metastasis Patients clinically manifest diabetes Acute chronic pancreatitis Clinically significant cardiac disease Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Open-label dose escalation ; BRAF inhibitor ; LGX818 ; PI3K inhibitor ; BYL719 ; EGFR ; cetuximab ; metastatic colorectal cancer ; KRAS ; BRAF ; V600</keyword>
</DOC>